MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company’s business at the 5th Annual LEERINK Partners Global Healthcare Conference.
The presentation at the LEERINK Partners conference is scheduled for 2:40pm ET on February 10, 2016, at the Waldorf Astoria Hotel in New York.
A replay of each presentation will be available via the investors section of the company’s website at www.intersectENT.com. The webcast replays will be archived for approximately one month.
About Intersect ENT
Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL® and PROPEL® mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
For additional information on the company or the products including risks and benefits please visit www.intersectENT.com.